RD 111
Alternative Names: Anti-CD 30 CAR-T cell therapy - Nanjing IASO Biotherapeutics; RD-111Latest Information Update: 28 Sep 2023
At a glance
- Originator Nanjing IASO Biotherapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported T-cell lymphoma
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in T-cell-lymphoma in China (Parenteral)
- 20 Aug 2019 Preclinical trials in T-cell lymphoma in China (Parenteral) (Nanjing IASO Biotherapeutics Pipeline, August 2019)